PFCS
OLMA icon

Pale Fire Capital SE’s Olema Pharmaceuticals OLMA Stock Holding History

Pale Fire Capital SE’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-44,000
Closed -$397K – 77
2023
Q2 		$397K Buy
+44,000
New +$266K 0.03% 38

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pale Fire Capital SE's OLMA Position: Q3 2023 in Review

Pale Fire Capital SE sold out of Olema Pharmaceuticals (OLMA) in Q3 2023, closing a stake of 44,000 shares — an estimated $397K sold.

Pale Fire Capital SE first reported a position in OLMA in Q2 2023 and held it in 1 quarter. The position peaked at $397K in Q2 2023. 97 funds tracked by Wall St. Rank hold OLMA as of Q3 2023.

  • Pale Fire Capital SE reported no remaining Olema Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Pale Fire Capital SE sold 44,000 Olema Pharmaceuticals shares in Q3 2023, an estimated $397K.
  • Pale Fire Capital SE first reported a position in Olema Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Pale Fire Capital SE's Olema Pharmaceuticals position peaked at $397K in Q2 2023.
  • 97 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2023.

Based on Pale Fire Capital SE's 13F filing for Q3 2023, filed 13 Nov 2023.